Tag Archives: DOJ

A First Win for Activists Challenging DOJ’s Right to Investigate Non-Criminals

27 Oct

The Oregon Court of Appeals has reversed a trial court’s dismissal of Farrell-Smith v. Oregon Department of Justice. The plaintiffs are suing the Oregon Department of Justice (ODOJ), the Attorney General, and the Chief Counsel of ODOJ’s Criminal Justice Division over their questionable authority to operate a domestic intelligence unit called the Oregon TITAN Fusion Center: Terrorism Information Threat Analysis Network. This is one of many nationwide intelligence hubs developed by the U.S. Department of Homeland Security to assess or anticipate threats post-9/11. The plaintiffs allege that TITAN surveils politicians and activists based on their views, instead of on any suspected criminality: and this is outside TITAN’s executive mandate.

Plaintiffs have presented evidence TITAN routinely monitors activists that oppose the Jordan Cove Liquified Natural Gas Pipeline, without a “criminal nexus” for these investigations. TITAN is also improperly colluding with a private PR firm (Teneo) and a pipeline-funded sheriff’s unit to gather information while bypassing Freedom of Information Act (FOIA) requirements. Privacy is also being violated when TITAN applies software to track on social media those who use the Black Lives Matter hashtag. And plaintiffs object to ODOJ’s secrecy in blocking public scrutiny and media record requests about demonstrations (i.e., Women’s March) by invoking broad “criminal intelligence” exemptions.

The trial court rejected the case partly because it interpreted the lawsuit as a request to shut down TITAN, whereas the Court of Appeals adjusted this aim to this being a challenge to the legality of TITAN’s cited operations. The case is asking: is it legal for a government agency to collect intelligence on citizens despite a lack of a suspicion of criminality? The appellate answer is that ODOJ is bound by the powers Oregon has assigned to it, or investigating: organized crime, public corruption or searching for investments of criminally implicated funds. Investigating outside these boundaries means TITAN is acting without a legal mandate. TITAN attempted to defend its actions by using loosely related laws, such as ORS 181A.250 that is inapplicable because it prohibits the collection of data based on political, religious or social views. The court rejected that obtaining a grant or a letter of acknowledgement from Governor Kitzhaber gave TITAL a special mandate.

There have been several federal lawsuits by civil liberties groups making FOIA requests to expose DHS-supported fusion centers spying on non-criminals. For example, a 2008 FOIA request revealed the Maryland Coordination and Analysis Center (MCAC) had investigated anti-death penalty and peace groups; the outcome of litigation was forcing the dismantling of the research files MCAC had gathered. And in 2025, ACLU v. Department of Justice was dismissed after a FOIA request succeeded in proving FBI’s Joint Terrorism Task Force and DHS fusion centers were investigating non-criminals by grouping radical causes with minorities and “domestic terrorism”. This Oregon case is a first state litigation that challenges the legality of such agencies to investigate non-criminals, as opposed to merely seeking FOIA data that this illegal surveillance exists. Legal scholars hope that if this Oregon case continues to see positive outcomes, it might help dismantle the 79 fusion centers across the U.S.

The lack of past accountability over these fusion centers might stem in conservatives’ successful attempts to redefine “communism”, “socialism” and other pro-justice and pro-humanist causes as amoral and thus equivalent to illegal. Mis-programmed voters tend to mis-define “communism” as totalitarianism or a lack of individual rights. They have been taught to assume there is something amoral about supporting equal rights for all, including racial and economic rights. It is in the interests of all humans to support other humans, but this re-programming turns this rational goodness into the opposite. The beneficiaries of this reversal are monopolists and pro-totalitarian rulers who prefer to limit rights: the opposite of the stated objective. Fusion centers are a present Big Brother experiment: it is an extreme form of totalitarian socialism of the Soviet variety. If DOJ’s entities are investigating non-criminals for conservatives’ political gains, they are not spending this time investigating the true criminals. Resources are being wasted to support one of two of America’s parties, while letting criminals continue criming to the detriment of us all.

Suggested Citation:
Faktorovich, Anna. “A First Win for Activists Challenging DOJ’s Right to Investigate Non-Criminals.” Anaphora’s Law Review (October 27, 2026).

Remunerating Doctors to Buy Blood Clot Treating Devices: Illegal?

27 Oct

On September 22, 2026, U.S. District Judge Gregory H. Woods dismissed a class-action securities fraud case: Michiana Area Electrical Workers’ Pension Fund v. Inari Medical Inc., et al. (2026). The investors had failed to prove with sufficient specificity that the company had engaged in an illegal doctor-kickback scheme or deliberately misled shareholders to inflate its stock price.

The evidence confirmed that Inari was providing up to $50,000 in corporate dinners, junkets a vacation destinations and NASCAR race tickets in exchange for doctors ordering Inari’s products. But such spending was found to be standard in this industry (according to the AdvaMed Code of Ethics on Interactions with Healthcare Professionals), as opposed to amounting to illegal kickbacks. The filers attempted to argue AdvaMed does specify a “per individual limit of $3,000 for gifts and promotional materials.” While one salesperson spent $50,000 on physician dinners over a three-month period, and another $5,000, each physician was not receiving over $3,000.

Inari is a manufacturer of technologies that treat and remove blood clots. The case was filed against Inari’s three former administrators: CEO, COO and CFO. They had operated a successful doctor-buttering scheme between 2021-4, before, on February 28, 2024, revealing to investors that they had received a civil investigative demand from the Department of Justice (DOJ), which was investigating if Inari’s practices were violating the Anti-Kickback Statute and the False Claims Act. This revelation led to a single-day 21% drop in Inari’s stock price, at a loss of $700 million in market capitalization.

Since this meant three invested pension funds had lost a lot of money, in May to June 2024, they filed a joint complaint over securities fraud and racketeering. One of the pension funds’ objections was that the administrators had collected $155.5 million in profits during the three years when the DOJ probe was active, but was not publicly disclosed by Inari.

The pension funds lost partly because DOJ’s probe failed to uncover evidence the gifts to physicians were illegal, and this meant the civil lawsuit lacked evidence underlying crimes had occurred. The administrators were allowed to delay disclosure until the date when they revealed it: they did not break the law by their delay. And they were acting in the best interests of shareholders by not disclosing earlier, since the stock would have plummeted earlier, and too soon before the DOJ had to report they had not found any prosecutable law-breaking. The filers might have assumed DOJ records would have what apparently failed to surface in discovery: they had no specific names of a doctor, date, or venue where a provably illegal transaction had taken place. All records proved was that Inari had spent a lot of money on sales and marketing.

The funds might have attached erroneous assumptions by the finding in the Purdue Pharma fraud case. It seems on the surface that Inari spending 68% of its revenue on sales and administration to cultivate customers was as illegal as what Purdue was doing. But in Purdue, the feds were able to prove systemic quid pro quo financial bribery in paying fraudulent “speaker fees” and consulting retainers well over the $3,000 limit to serve as pushers of prescriptions that they were fraudulently selling as safe when they were deadly addictive. There was nothing proven to be fraudulent with Inari’s core devices. Most small businesses wish it was illegal for giant corporations to spend such enormous sums on convincing people to buy their products. But his is how capitalism works: not the best products but the most effective sales campaigns win market share. The legality of Inari’s actions should have been apparent through brisk disclosures without a years-long DOJ audit. If DOJ had dropped their case upon failing to find wrongdoing, investors would not have lost millions in a panic sell-off. The public is too trusting in government actions: when the government declares it is auditing somebody, the public assumes the entity is guilty before the test results come in.

Suggested Citation:
Faktorovich, Anna. “Remunerating Doctors to Buy Blood Clot Treating Devices: Illegal?” Anaphora’s Law Review (October 27, 2026).